Brief: Aurinia Announces Positive Results From Phase 1 Study Of Aritinercept
30/06/2025 11:07
June 30 (Reuters) - Aurinia Pharmaceuticals Inc AUPH.O: AURINIA ANNOUNCES POSITIVE RESULTS FROM PHASE 1 STUDY OF ARITINERCEPT (AUR200) AURINIA PHARMACEUTICALS INC - SINGLE DOSES OF ARITINERCEPT LED TO LONG-LASTING REDUCTIONS IN IMMUNOGLOBULINS AURINIA PHARMACEUTICALS INC - ARITINERCEPT WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS AURINIA PHARMACEUTICALS INC - PLANS TO INITIATE CLINICAL STUDIES IN TWO AUTOIMMUNE DISEASES AURINIA PHARMACEUTICALS: PLAN TO INITIATE CLINICAL STUDIES IN AT LEAST TWO AUTOIMMUNE DISEASES IN SECOND HALF OF THIS YEAR Source text: ID:nBw9dByd2a Further company coverage: AUPH.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Aurinia Pharmaceuticals
See all newsBrief: Aurinia Settles Patent Litigation With Teva
Canada's Aurinia Q2 revenue rises on LUPKYNIS sales
Brief: Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million
Aurinia Pharmaceuticals Inc expected to post earnings of 24 cents a share - Earnings Preview
Brief: Lupkynis Associated With A Statistically Significant 53% Reduction In Risk Of Renal-Related Event Or Death